Eisai Emea company information, Employees & Contact Information

Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation PR Newswire

Eli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costs Pharmaceutical Technology

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia Biogen

In UK, it's strike 2 for Alzheimer's treatments from Lilly and Biogen/Eisai Fierce Pharma

U.K. decision blocks a pair of Alzheimer’s drugs from access through its national health service statnews.com

EISAI OPENS NEW PACKAGING FACILITY AT HATFIELD PRODUCTION PLANT IN U.K. Eisai Co., Ltd.

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission Biogen

Simmons & Simmons advises Eisai Co., Ltd. on the sale to H.A.C. Simmons & Simmons

Dentons advises H.A.C. Pharma on Strategic Acquisition of European and UK Rights of the medicinal product TARGRETIN Dentons

Breakthrough Alzheimer's drugs too pricey to be offered on NHS BBC

Production and Logistics (Demand Chain Systems) Eisai Co., Ltd.

Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories Yahoo Finance

UK approves Leqembi, but reimbursement may not follow BioPharma Dive

Leqembi® (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain Biogen

Chapter 6 Breaking into the Top 20 Worldwide Eisai Co., Ltd.

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease Biogen

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA Biogen

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Biogen

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia Biogen

Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia Biogen

Combination of Merck’s Keytruda with Eisai’s Lenvima Fail Phase III Trial in Melanoma Clinical Trials Arena

Eisai, Biogen's Leqembi nabs UK nod, but reimbursement remains elusive Fierce Pharma

“LEQEMBI® Intravenous Infusion” (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20 Biogen

New Alzheimer's drug deemed too costly for UK's state-run health service Reuters

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union Biogen

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (A Biogen

Japanese Pharmaceutical Company Eisai Expands UK Site with New Facility PR Newswire UK

Biogen, Eisai’s Leqembi Gets UK Approval but Deemed Too Expensive by NICE BioSpace

Eribulin for the treatment of advanced breast cancer: A prospective observational registry study Wiley Online Library

Eisai and UCL confirm an extension of the Drug Discovery and Development Collaboration Agreement University College London

Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug Reuters

MSD and Eisai’s combination therapy recommended by NICE for advanced endometrial cancer PMLiVE

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China Stock Titan

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody Alzheimer's Research & Therapy

425,000 Patients Affected: Australia Approves LEQEMBI for Early Alzheimer's Disease Treatment Stock Titan

Eisai considers legal action over NICE delay of Lenvima Fierce Pharma

Heal thyself University of Cambridge

Eisai opens new European HQ in the UK Pharmafile

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine | British Journal of Cancer Nature

Eisai pharmaceuticals and UCL form drug discovery alliance | UCL News - UCL University College London

Leqembi enters second consultation period following NICE draft guidance update PharmaTimes

Launching: £2m collaboration with Eisai to accelerate UK DRI

Newly licensed Alzheimer’s drug, lecanemab, not available on NHS Alzheimer's Research UK

Innovation: MHRA helps Eisai with state-of-the-art facility GOV.UK

UK Dementia Research Institute responds to NICE guidance on UK DRI

Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma Nature

R (on the application of Eisai Ltd) v National Institute for Health & Clinical Excellence (NICE) & (1) Shire Pharmaceuticals Ltd (2) Association of the British Pharmaceutical Industry (Interveners) blackstonechambers.com

Pharmaceutical Giant Eisai Hit by Ransomware Attack The Japan News

Sector leaders to drive progress on national Dame Barbara Windsor Mission to beat dementia GOV.UK

Dr Haruo Naito honoured by The Queen GOV.UK

Hilary Evans and Nadeem Sarwar appointed co-chairs of national Dementia Mission Caring Times

Health | Snail venom painkiller launched BBC